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SUMMARY. Spacer devices are used to optimize airway aerosol deposition from pressurized metered-dose
inhalers (pMDI). The in vitro performance of the combination fluticasone/salmeterol pMDI alone and con-
nected to 3 different valved holding chambers (VHC) was compared by measuring impactor entry port
(“throat”) deposition and fine particle dose (FPD) of each medication. Salmeterol (SX) and Fluticasone
(FP) throat deposition was reduced over 90 % by all VHC compared to pMDI alone (p < 0,001). The FPD
obtained from pMDI alone and connected to VHCs Vortex®, AeroChamber Plus® and Able Spacer® for
Salmeterol (25 μg nominal dose) were 12.2 ± 0.7, 12.5 ± 0.5, 11.6 ± 0.8, and 7.9 ± 0.9 μg, respectively. For
Fluticasone (125 μg nominal dose) the FPD were 42.5 ± 2.6, 36.3 ± 3.1, 39.8 ± 2.4, and 22.8 ± 3.5 μg, respec-
tively. There were no statistical differences in FPD between devices, except for AbleSpacer® that delivered
a lower FPD for both drugs (p < 0.001).
